Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Oktober 2020 07:30 ET | Quelle: Centrexion Therapeutics

Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a biotechnology company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs and...
03. Dezember 2019 08:00 ET | Quelle: Centrexion Therapeutics

Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975

BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today announced...
08. November 2019 08:00 ET | Quelle: Centrexion Therapeutics

Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly

BOSTON, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today announced...
17. September 2019 08:00 ET | Quelle: Centrexion Therapeutics

Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with Moderate-to-Severe Osteoarthritis Knee Pain

- CNTX-4975 Phase 3 clinical development program fully enrolled - - VICTORY-1 pivotal and VICTORY-3 open-label topline results expected in Q1 2020; VICTORY-2 pivotal results expected in Q3 2020 - ...
04. September 2019 11:11 ET | Quelle: Centrexion Therapeutics

CORRECTION - Centrexion Therapeutics

BOSTON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- In a release issued earlier today by Centrexion Therapeutics Corporation (NASDAQ: CNTX), please note that the headline should read "Centrexion Therapeutics...
18. Juli 2019 07:30 ET | Quelle: Centrexion Therapeutics

Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined CNTX-4975 Administration Techniques

-- Administration procedure designed to optimize physician and patient experience and convenience -- -- Company also shares interim analysis of 719 patients in VICTORY-3 Phase 3 open-label trial...
11. Juni 2019 07:30 ET | Quelle: Centrexion Therapeutics

Centrexion Therapeutics to Announce CNTX-4975 Trial Results at the European League Against Rheumatism’s (EULAR) 2019 Annual European Congress of Rheumatology

BOSTON, June 11, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today...
05. Juni 2019 07:30 ET | Quelle: Centrexion Therapeutics

Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical Trial of Repeat Doses of CNTX-4975 in Patients with Moderate to Severe Osteoarthritis Knee Pain

BOSTON, June 05, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today...
29. April 2019 08:25 ET | Quelle: Centrexion Therapeutics

Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 British Society for Rheumatology Annual Conference and Osteoarthritis Research Society International 2019 World Congress

BOSTON, April 29, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today...
27. März 2019 07:30 ET | Quelle: Centrexion Therapeutics

Centrexion Therapeutics Announces Publication of Phase 2 Efficacy Data on CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain in Arthritis & Rheumatology

BOSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation (Centrexion), a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain,...

Nächste Seite